The division of Cytopathology at Anatomical Pathology PathWest provides quality laboratory service, teaching and advice to health professionals.

Our team of experts offers comprehensive services in the following two major areas:

The National Cervical Screening Programme

We provide a cervical cancer screening service with both human papillomavirus (HPV) DNA testing and cytology analysis. We process liquid-based cytology (LBC) samples (SurePath and ThinPrep) and accredited self-collected vaginal swab samples. Cytology slide preparations made from liquid SurePath samples are examined by experienced scientists who use computer-assisted screening in line with best practice guidelines. Furthermore, all cytology slide preparations are manually screened by two separate scientists and viewed by a specialist pathologist prior to reporting.

Non-gynaecologic Cytology Service


We provide rapid on-site evaluation of image-guided fine needle aspirations (FNAs) performed in the public sector. We process a large number of FNA samples collected and referred by several private radiology providers and public hospitals throughout Western Australia. We offer a direct FNA service for the prompt investigation of palpable lumps. It involves a consultation with a Cytopathologist who performs on-site evaluation of specimen adequacy, triages material for ancillary studies, liaises with general practitioners and specialists. Finally, we perform abdominal fat pad aspiration for investigation of systemic amyloidosis by prior appointment.

We receive and process body fluid and exfoliative cytology samples (respiratory, urogenital, effusions, cerebrospinal fluids, among others) collected from inpatients and outpatients from all public hospitals in Western Australia.

Semen analysis for fertility and post-vasectomy samples is offered at the Queen Elizabeth II Medical Centre. Our team includes Cytopathologists and several highly skilled medical scientists.

We also provide a unique, highly specialised core biopsy imprint cytology assessment for public patients with either screen-detected or symptomatic breast lesions.

Last Updated: 18/10/2021